These findings demonstrated that combined administration of ACLY inhibitor ETC-1002 and IGF1R inhibitor Linsitinib significantly inhibited HOXA13-mediated CRC metastasis (Fig. 6F). Here, HOXA13 is linked to colorectal carcinoma.